CDC shortens Pfizer booster recommendation, adds recommendation for immunocompromised children

The Centers for Disease Control and Prevention signed off on two measures to increase access to Pfizer booster doses today.

The CDC recommended shortening the Pfizer booster eligibility interval from six months to five months. This would apply to anyone who received the Pfizer vaccine series initially. The recommendation has not changed for Johnson & Johnson or Moderna vaccine recipients at this time.

The CDC also recommends that moderately and severely immunocompromised 5-to-11 year olds get an additional primary dose of the vaccine 28 days after their second shot. The Pfizer COVID-19 vaccine is still the only vaccine recommended and authorized for children ages 5-to-11.

This recommendation is consistent with the CDC’s prior recommendation for adults.

“As we have done throughout the pandemic, we will continue to update our recommendations to ensure the best possible protection for the American people,” said CDC Director Rochelle Walensky in a statement. “Following the FDA’s authorizations, today’s recommendations ensure people are able to get a boost of protection in the face of Omicron and increasing cases across the country, and ensure that the most vulnerable children can get an additional dose to optimize protection against COVID-19.”
This decision comes after Monday moves from the Food and Drug Administration. The CDC’s Advisory Committee on Immunization Practices plans to meet Wednesday to discuss the FDA’s authorization of boosters for kids ages 12 to 15.